68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Inclusion Criteria:

   - Histopathological proven prostate adenocarcinoma

   - Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or
   radiation therapy (external beam or brachytherapy)

      - Post radical prostatectomy (RP) - American Urology Association (AUA)
      recommendation

         - PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP

         - Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA
         measurements greater than 0.2 ng/mL)

      - Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix
      consensus definition

         - A rise of PSA measurement of 2 or more ng/mL over the nadir

   - Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group [ECOG] /
   World Health Organization [WHO] equivalent)

   - Able to provide written consent

Exclusion Criteria:

   - Investigational therapy for prostate cancer.

   - Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.

   - Prior history of any other malignancy within the last 2 years, other than skin basal
   cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
   superficial bladder cancer.